Option Care Health Misses Q1 Revenue Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy OPCH?
Source: Yahoo Finance
- Weak Revenue Growth: Option Care Health's Q1 revenue grew only 1.3% year-on-year to $1.35 billion, falling short of the $1.40 billion analyst expectations, indicating pressure in market competitiveness.
- Profitability Performance: Although the adjusted EPS of $0.40 exceeded the analyst forecast of $0.37 by 8.1%, the overall performance was constrained by slower-than-expected revenue growth, impacting investor confidence.
- Guidance Downgrade: The company lowered its full-year revenue guidance to $5.73 billion from $5.9 billion, a 3% decrease, reflecting management's cautious outlook on future market conditions, which may affect long-term shareholder returns.
- Strategic Investments and Challenges: Management emphasized increasing investments in the commercial team to address the decline in chronic therapy patient volumes while optimizing cost structures to maintain profitability, demonstrating the company's determination to seek growth amid adversity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OPCH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OPCH
Wall Street analysts forecast OPCH stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 20.330
Low
27.00
Averages
36.22
High
40.00
Current: 20.330
Low
27.00
Averages
36.22
High
40.00
About OPCH
Option Care Health, Inc. is an independent provider of home and alternate site infusion services. The Company’s infusion services include the clinical management of infusion therapy, nursing support and care coordination. It provides a therapy portfolio through its network of 92 full-service pharmacies and 93 stand-alone ambulatory infusion suites. It administers a wide variety of therapies and services, including anti-infectives infusion, nutrition support, immunoglobulin infusion, chronic inflammatory disorders, neurological disorders, bleeding disorders infusion, Naven health, women’s health, heart failure, and others. Its home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient’s condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Option Care Health Misses Q1 Revenue Expectations
- Weak Revenue Growth: Option Care Health's Q1 revenue grew only 1.3% year-on-year to $1.35 billion, falling short of the $1.40 billion analyst expectations, indicating pressure in market competitiveness.
- Profitability Performance: Although the adjusted EPS of $0.40 exceeded the analyst forecast of $0.37 by 8.1%, the overall performance was constrained by slower-than-expected revenue growth, impacting investor confidence.
- Guidance Downgrade: The company lowered its full-year revenue guidance to $5.73 billion from $5.9 billion, a 3% decrease, reflecting management's cautious outlook on future market conditions, which may affect long-term shareholder returns.
- Strategic Investments and Challenges: Management emphasized increasing investments in the commercial team to address the decline in chronic therapy patient volumes while optimizing cost structures to maintain profitability, demonstrating the company's determination to seek growth amid adversity.
See More
Bank of America Downgrades Option Care Health Rating
- Rating Downgrade Impact: Bank of America downgraded Option Care Health (OPCH) from Buy to Neutral, primarily due to its lowered full-year revenue outlook, resulting in continued stock price decline post-earnings, reflecting market concerns about the company's future growth.
- Revenue Forecast Adjustment: Analyst Joanna Gajuk projected that OPCH will face pressures from payor therapy authorizations and competition from pharmacy benefit manager-owned pharmacies, particularly related to Johnson & Johnson's (JNJ) Stelara, leading to reduced revenue and EBITDA estimates.
- Significant Price Target Cut: Gajuk nearly halved OPCH's price target from $40 to $22, indicating a lack of confidence in the company's ability to return to prior long-term targets, with expectations that the stock will remain range-bound without upward momentum.
- Cautious Future Outlook: Although Option Care Health forecasts 2026 revenue between $5.675 billion and $5.775 billion, with EBITDA between $480 million and $505 million, analysts believe the stock will struggle to break current limits until more proof points emerge regarding its recovery potential.
See More
Option Care Health Q1 2026 Earnings Call Insights
- Weak Revenue Growth: Option Care Health reported Q1 revenue of $1.4 billion, reflecting only a 1% year-over-year increase that fell short of expectations, indicating pressure from market competition, particularly in its autoimmune and chronic inflammatory portfolio where patient census reset was greater than anticipated.
- Adjusted Full-Year Guidance: The company revised its full-year net revenue guidance down to a range of $5.675 billion to $5.775 billion, highlighting that industry dynamics were more impactful than expected, although it maintained its EBITDA and adjusted EPS projections at $480 million to $505 million.
- Enhanced Financial Flexibility: During the quarter, the company expanded its revolving credit facility from $400 million to $850 million, a strategic move aimed at bolstering financial flexibility, which will help sustain operations and investment capabilities amid an uncertain market environment.
- Market Share Loss: Management acknowledged challenges in patient retention, estimating a gross profit headwind of approximately $55 million primarily due to competitors processing patients more quickly and changes in patient insurance plans, which could negatively impact future revenue growth.
See More
Block & Leviton Investigates Option Care Health for Securities Violations
- Stock Price Plunge: Option Care Health, Inc. saw its stock drop over 30% on April 30, 2026, following the release of its first-quarter results and a cut in its full-year revenue guidance, primarily due to an unexpected reset in patient census in its chronic inflammatory disease portfolio, including conversions of the Stelara biosimilar.
- Revenue Guidance Cut: Earlier in 2026, the company had maintained its full-year revenue guidance and stated that its related patient census assumptions were aligned with expectations, but this adjustment indicates a significant shift in market demand, potentially undermining investor confidence.
- Legal Investigation Launched: Block & Leviton is investigating whether Option Care Health committed securities law violations and may file actions to recover losses on behalf of investors, indicating that the company faces legal risks that could impact its future financial performance.
- Investor Action Recommendation: Affected investors are encouraged to contact Block & Leviton to learn how to recover their losses, demonstrating the firm's proactive stance in protecting investor rights while potentially attracting more investor attention to the company's legal compliance.
See More
Investigation into Option Care Health Investor Claims
- Declining Financial Performance: Option Care Health reported Q1 2026 net revenue of $1.35 billion, reflecting only a 1.3% year-over-year growth, while adjusted EBITDA fell by 6.3%, indicating a significant decline in profitability that could undermine investor confidence.
- Guidance Downgrade: The company lowered its full-year 2026 net revenue guidance to a range of $5.675 billion to $5.775 billion, down from the previous $5.8 billion to $6.0 billion, reflecting a pessimistic outlook on future performance that may lead to further stock price declines.
- Chronic Business Growth Slowdown: The report indicated a decline in revenue growth from the chronic business, with the chronic inflammatory disease portfolio expected to create an approximately 600 basis point headwind to total company net revenue growth in 2026, exacerbating investor concerns.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Option Care Health complied with federal securities laws, and investors who suffered losses from holding the company's stock may have the opportunity to seek compensation through legal channels, highlighting concerns over corporate governance and compliance.
See More
Option Care Health Q1 Revenue Misses Expectations, Lowers Full-Year Outlook
- Revenue Performance Miss: Option Care Health reported $1.4 billion in Q1 2026 revenue with approximately 2% YoY growth, falling short of Street forecasts by $50 million, indicating a lack of growth momentum that could undermine investor confidence moving forward.
- Adjusted EPS Beats Expectations: Despite the revenue miss, the company’s adjusted EPS of $0.40 exceeded consensus by $0.03, demonstrating effective cost management that may alleviate some investor concerns amidst the disappointing revenue figures.
- Full-Year Revenue Outlook Cut: The company lowered its full-year revenue guidance to $5.675 billion - $5.775 billion, down from the previous $5.8 billion - $6.0 billion forecast, which could lead to diminished market confidence in the company’s growth potential.
- Operating Margin Decline: The operating margin for Q1 stood at 5.4%, down from 5.9% in the prior year, indicating challenges in cost management and operational efficiency that may impact long-term profitability and competitive positioning.
See More
Option Care Health Misses Q1 Revenue Expectations
- Weak Revenue Growth: Option Care Health's Q1 revenue grew only 1.3% year-on-year to $1.35 billion, falling short of the $1.40 billion analyst expectations, indicating pressure in market competitiveness.
- Profitability Performance: Although the adjusted EPS of $0.40 exceeded the analyst forecast of $0.37 by 8.1%, the overall performance was constrained by slower-than-expected revenue growth, impacting investor confidence.
- Guidance Downgrade: The company lowered its full-year revenue guidance to $5.73 billion from $5.9 billion, a 3% decrease, reflecting management's cautious outlook on future market conditions, which may affect long-term shareholder returns.
- Strategic Investments and Challenges: Management emphasized increasing investments in the commercial team to address the decline in chronic therapy patient volumes while optimizing cost structures to maintain profitability, demonstrating the company's determination to seek growth amid adversity.
See More
Bank of America Downgrades Option Care Health Rating
- Rating Downgrade Impact: Bank of America downgraded Option Care Health (OPCH) from Buy to Neutral, primarily due to its lowered full-year revenue outlook, resulting in continued stock price decline post-earnings, reflecting market concerns about the company's future growth.
- Revenue Forecast Adjustment: Analyst Joanna Gajuk projected that OPCH will face pressures from payor therapy authorizations and competition from pharmacy benefit manager-owned pharmacies, particularly related to Johnson & Johnson's (JNJ) Stelara, leading to reduced revenue and EBITDA estimates.
- Significant Price Target Cut: Gajuk nearly halved OPCH's price target from $40 to $22, indicating a lack of confidence in the company's ability to return to prior long-term targets, with expectations that the stock will remain range-bound without upward momentum.
- Cautious Future Outlook: Although Option Care Health forecasts 2026 revenue between $5.675 billion and $5.775 billion, with EBITDA between $480 million and $505 million, analysts believe the stock will struggle to break current limits until more proof points emerge regarding its recovery potential.
See More
Option Care Health Q1 2026 Earnings Call Insights
- Weak Revenue Growth: Option Care Health reported Q1 revenue of $1.4 billion, reflecting only a 1% year-over-year increase that fell short of expectations, indicating pressure from market competition, particularly in its autoimmune and chronic inflammatory portfolio where patient census reset was greater than anticipated.
- Adjusted Full-Year Guidance: The company revised its full-year net revenue guidance down to a range of $5.675 billion to $5.775 billion, highlighting that industry dynamics were more impactful than expected, although it maintained its EBITDA and adjusted EPS projections at $480 million to $505 million.
- Enhanced Financial Flexibility: During the quarter, the company expanded its revolving credit facility from $400 million to $850 million, a strategic move aimed at bolstering financial flexibility, which will help sustain operations and investment capabilities amid an uncertain market environment.
- Market Share Loss: Management acknowledged challenges in patient retention, estimating a gross profit headwind of approximately $55 million primarily due to competitors processing patients more quickly and changes in patient insurance plans, which could negatively impact future revenue growth.
See More
Block & Leviton Investigates Option Care Health for Securities Violations
- Stock Price Plunge: Option Care Health, Inc. saw its stock drop over 30% on April 30, 2026, following the release of its first-quarter results and a cut in its full-year revenue guidance, primarily due to an unexpected reset in patient census in its chronic inflammatory disease portfolio, including conversions of the Stelara biosimilar.
- Revenue Guidance Cut: Earlier in 2026, the company had maintained its full-year revenue guidance and stated that its related patient census assumptions were aligned with expectations, but this adjustment indicates a significant shift in market demand, potentially undermining investor confidence.
- Legal Investigation Launched: Block & Leviton is investigating whether Option Care Health committed securities law violations and may file actions to recover losses on behalf of investors, indicating that the company faces legal risks that could impact its future financial performance.
- Investor Action Recommendation: Affected investors are encouraged to contact Block & Leviton to learn how to recover their losses, demonstrating the firm's proactive stance in protecting investor rights while potentially attracting more investor attention to the company's legal compliance.
See More
Investigation into Option Care Health Investor Claims
- Declining Financial Performance: Option Care Health reported Q1 2026 net revenue of $1.35 billion, reflecting only a 1.3% year-over-year growth, while adjusted EBITDA fell by 6.3%, indicating a significant decline in profitability that could undermine investor confidence.
- Guidance Downgrade: The company lowered its full-year 2026 net revenue guidance to a range of $5.675 billion to $5.775 billion, down from the previous $5.8 billion to $6.0 billion, reflecting a pessimistic outlook on future performance that may lead to further stock price declines.
- Chronic Business Growth Slowdown: The report indicated a decline in revenue growth from the chronic business, with the chronic inflammatory disease portfolio expected to create an approximately 600 basis point headwind to total company net revenue growth in 2026, exacerbating investor concerns.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Option Care Health complied with federal securities laws, and investors who suffered losses from holding the company's stock may have the opportunity to seek compensation through legal channels, highlighting concerns over corporate governance and compliance.
See More
Option Care Health Q1 Revenue Misses Expectations, Lowers Full-Year Outlook
- Revenue Performance Miss: Option Care Health reported $1.4 billion in Q1 2026 revenue with approximately 2% YoY growth, falling short of Street forecasts by $50 million, indicating a lack of growth momentum that could undermine investor confidence moving forward.
- Adjusted EPS Beats Expectations: Despite the revenue miss, the company’s adjusted EPS of $0.40 exceeded consensus by $0.03, demonstrating effective cost management that may alleviate some investor concerns amidst the disappointing revenue figures.
- Full-Year Revenue Outlook Cut: The company lowered its full-year revenue guidance to $5.675 billion - $5.775 billion, down from the previous $5.8 billion - $6.0 billion forecast, which could lead to diminished market confidence in the company’s growth potential.
- Operating Margin Decline: The operating margin for Q1 stood at 5.4%, down from 5.9% in the prior year, indicating challenges in cost management and operational efficiency that may impact long-term profitability and competitive positioning.
See More
